Drugs / AB-101
Trials 6
News releases announcing trial results or a regulatory action · 26
| Date | Issuer | Release |
|---|---|---|
| 2026-10-02 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 artivabio.com ↗
AB-101, Outpatient-Administered, Non-Genetically Modied NK Cells in Combination with Rituximab Generate Robust Ecacy Responses Comparable with Autologous CAR T in 34 Patients with Rheumatologic Diseases |
| 2026-10-01 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) artivabio.com ↗
Oral presentation includes safety and ecacy data as of the July 2, 2026 data cuto, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren disease |
| 2026-06-08 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today artivabio.com ↗
Late-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseases |
| 2026-05-19 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases artivabio.com ↗ |
| 2026-05-08 | Artiva Biotherapeutics, Inc. | Results Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 artivabio.com ↗
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents |
| 2025-11-12 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease artivabio.com ↗ |
| 2025-11-03 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® artivabio.com ↗
Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a favorable tolerability prole observed to date and the feasibility of patient management in outpatient rheumatology clinics |
| 2025-10-16 | Artiva Biotherapeutics, Inc. | Regulatory Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update artivabio.com ↗ |
| 2025-05-13 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting artivabio.com ↗
Median duration of response for AlloNK + rituximab not yet reached and is at least 19.4 months, in line with approved auto-CAR-T therapies in aggressive B-NHL |
| 2025-05-08 | Artiva Biotherapeutics, Inc. | Regulatory Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights artivabio.com ↗
Following Investigational New Drug application clearance by the U.S. Food and Drug Administration, initiating global Phase 2a company-sponsored basket clinical trial for AlloNK + rituximab for refractory rheumatoid arthritis (RA), Sjögren’s disease, idiopathic inammatory myopathies (myositis, or IIM) and systemic sclerosis (scleroderma, or SSc), with site initiation underway |
| 2025-04-28 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting artivabio.com ↗
These results demonstrate prolonged duration of response, deep B-cell depletion and a well-tolerated safety prole of AlloNK in combination with rituximab. |
| 2025-03-10 | Alphyn Biologics | Results Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis alphynbiologics.com ↗
The Phase 2a clinical trial program met all primary and secondary endpoints, demonstrating Zabalafin Hydrogel significantly improved pruritus (itch), quality of life, inflammation, as well as control of bacteria-associated and other AD flares, and clearance of infected AD skin. |
| 2025-02-19 | Alphyn Biologics | Regulatory Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment alphynbiologics.com ↗ |
| 2024-03-07 | Alphyn Biologics | Results Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis alphynbiologics.com ↗ |
| 2024-02-22 | Artiva Biotherapeutics, Inc. | Regulatory Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis artivabio.com ↗
announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AlloNK® (also known as AB-101) for the treatment of lupus nephritis (LN) in combination with rituximab or obinutuzumab. |
| 2023-08-16 | Artiva Biotherapeutics, Inc. | Regulatory Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis artivabio.com ↗
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis |
| 2023-07-14 | Alphyn Biologics | Results Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection alphynbiologics.com ↗
The interim results evaluating AB-101a on the immune and bacterial components of AD show the therapeutic candidate is meeting all endpoints for efficacy and safety. |
| 2023-07-10 | Alphyn Biologics | Results Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis alphynbiologics.com ↗ |
| 2023-05-25 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting artivabio.com ↗
AB-101 was well tolerated at up to four billion cells per dose as a monotherapy; up to 16 doses of AB-101 at one billion cells per dose were successfully administered in combination with rituximab in an outpatient setting |
| 2023-05-04 | Alphyn Biologics | Results Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial alphynbiologics.com ↗
The first-of-its-kind trial met all primary and secondary efficacy endpoints in the pediatric population ages 2 and older with minimal safety and side effects. |
| 2023-04-27 | Alphyn Biologics | Results Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress alphynbiologics.com ↗
This pediatric population met all of its primary clinical trial endpoints. |
| 2023-01-31 | Artiva Biotherapeutics, Inc. | Regulatory Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101 artivabio.com ↗
Granted Fast Track designation by U.S. FDA for the treatment of relapsed/refractory non-Hodgkin lymphoma of B cell origin, in combination with rituximab |
| 2023-01-04 | Alphyn Biologics | Results Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment alphynbiologics.com ↗
Alphyn Biologics , a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a topical therapeutic for mild-to-moderate atopic dermatitis (AD). |
| 2022-11-10 | Artiva Biotherapeutics, Inc. | Results Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting artivabio.com ↗
Data highlights the optimized cell prole of AB-101 and combination data with monoclonal antibodies rituximab, obinutuzumab, cetuximab, and trastuzumab |
| 2022-11-03 | Artiva Biotherapeutics, Inc. | Results Artiva Announces Abstract Accepted for Presentation at the 64th American Society of Hematology Annual Meeting & Exposition artivabio.com ↗ |
| 2020-12-07 | Artiva Biotherapeutics, Inc. | Regulatory Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas artivabio.com ↗
Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas |
All press releases naming this drug 33 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06265220 ↗ |
| Known as | AlloNK | “AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells.” NCT06265220 ↗ |
| Action | Inhibit | “PD-L1 checkpoint inhibitor” NCT05960240 ↗ |
| Modality | Cell therapy | “AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells.” NCT04673617 ↗ |
| Route | Intravenous | “NK cell therapy, intravenous infusion” NCT05883449 ↗ |